SuperGen (Nasdaq: SUPG) announced that it has received clearance to initiate clinical trials with SGI-1776, an inhibitor of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE